Amgen reports first phase 3 win for $400M eczema drug, but Dupixent rivalry doubts remain

Amgen reports first phase 3 win for $400M eczema drug, but Dupixent rivalry doubts remain ntaylor Wed, 09/25/2024 - 05:29